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Background: Biochemical markers harvested from gingival crevic-
ular fluid (GCF) may be useful to identify and predict periodontal
disease progression and to monitor the response to treatment. C-
telopeptide pyridinoline cross-links (ICTP), a host-derived breakdown
product specific for bone, and interleukin-1β (IL-1), a potent bone-
resorptive cytokine, have been associated with periodontal tissue
destruction. The aim of this study was to examine the effect of non-
surgical periodontal therapy on GCF levels of ICTP and IL-1.
Methods: Twenty-five chronic periodontitis subjects were moni-
tored at 8 sites per subject at baseline prior to scaling and root plan-
ing and 1, 3, and 6 months after therapy. Four shallow (probing
depths <4 mm) and 4 deep (probing depths ≥5 mm) sites were mon-
itored for both marker levels and clinical parameters. GCF was col-
lected for 30 seconds on paper strips, and levels of ICTP and IL-1 were
determined using radioimmunoassay (RIA) and enzyme-linked
immunosorbent assay (ELISA) techniques, respectively. Clinical mea-
surements included probing depth (PD), clinical attachment level
(CAL), and bleeding on probing (BOP).
Results: Deep sites exhibited significantly (P <0.001) higher ICTP
and IL-1 levels compared to shallow sites at all time intervals. ICTP
demonstrated a stronger association to clinical parameters than IL-
1 including a modest correlation (r = 0.40, P <0.001) between ICTP
and attachment loss. Significant improvements in PD, CAL, and BOP
were observed at 1, 3, and 6 months in all sites (P <0.01). However,
non-surgical mechanical therapy did not significantly reduce ICTP
and IL-1 levels over the 6-month period. Further examination of sub-
jects based on smoking status revealed that ICTP levels were signif-
icantly reduced at 3 and 6 months and IL-1 levels reduced at 3
months among non-smokers only.
Conclusions: A single episode of non-surgical mechanical ther-
apy did not significantly reduce biochemical markers associated with
bone resorption in patients exhibiting chronic periodontitis. Future
longitudinal studies are warranted to specifically evaluate the rela-
tionship between C-telopeptide pyridinoline cross-links and peri-
odontal disease progression. J Periodontol 2001;72:1045-1051.
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Traditional methods used in thediagnosis of periodontal dis-ease include assessments of
gingival inflammation (e.g., bleed-
ing on probing) and periodontal tis-
sue destruction (e.g., probing depth
[PD], clinical attachment level [CAL]).
Advantages associated with these
methods include being easy to use,
cost-effective, and relatively non-
invasive.1 However, the major dis-
advantage of these techniques is
that they are static diagnostic para-
meters, indicating disease history
and not current disease status.2
Therefore, these methods cannot
identify highly susceptible patients
or actively deteriorating sites. In
addition, limitations in measure-
ment reliability necessitate a
change of 2 to 3 mm before a site
can be identified as having experi-
enced a significant anatomic
event.3,4 Thus, there is a need for
the development of new diagnostic
tests that can detect the presence of
active disease, predict future dis-
ease progression, and evaluate the
response to periodontal therapy,
therefore improving the clinical man-
agement of periodontal patients.5
A potential new diagnostic in-
volves the direct measurement in
the gingival crevicular fluid (GCF)
of a bone-specific molecule called
pyridinoline cross-linked carboxy-
terminal telopeptide of Type I colla-
gen (ICTP). The value of pyridino-
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line cross-links as markers of bone turnover stems from
their specificity for bone. In skin and other soft tissues,
histidine cross-links are the predominant form, and no
pyridinoline-like structures exist.6 The measurement of
pyridinoline cross-links is currently used as a diagnos-
tic marker of active bone resorption in metabolic bone
diseases such as postmenopausal osteoporosis.7 The
presence of ICTP in GCF has been associated with bone
and attachment loss in experimental and natural peri-
odontitis.8,9 In an experimental periodontitis model,
ICTP was found to be highly sensitive and predictive
for future radiographic bone loss as measured by com-
puter-assisted digital radiography.8 More recently, it has
been demonstrated that ICTP is elevated in periodon-
tal patients exhibiting high levels of putative periodon-
tal pathogens including Bacteroides forsythus, Por-
phyromonas gingivalis, Fusobacterium nucleatum
subspecies, and Treponema denticola.9 Elevated levels
of ICTP have also been observed around dental implants
colonized by organisms associated with disease pro-
gression.10 Finally, treatment with a matrix metallo-
proteinase (MMP) inhibitor significantly reduced ICTP
levels in patients exhibiting active periodontal disease.11
The results of these studies suggest that utilization of
ICTP as a diagnostic marker may be useful to identify
and predict periodontal disease progression and to
monitor the response to treatment.
Interleukin-1 (IL-1) is a potent bone-resorbing
cytokine formerly known as osteoclast activating fac-
tor.12 Sources of IL-1 include monocytes, neutrophils,
fibroblasts, and epithelial cells.1 IL-1β is the major form
secreted by monocytes, and its production is stimulated
by bacterial lipopolysaccharide.13 Once secreted, IL-1
may activate lymphocytes, incite macrophage chemo-
taxis and prostaglandin production, and stimulate
osteoclastic resorption of bone.14 IL-1 has been
detected in both periodontal tissues and GCF in
patients with periodontal disease.15,16 Site-specific ele-
vations have been reported in untreated periodontitis
populations and during induction of gingival inflam-
mation.17-19 Conflicting results have been reported
regarding the effect of periodontal treatment on IL-1
levels.19-21
The aims of the present study were to examine the
effect of non-surgical periodontal therapy (scaling and
root planing [SRP]) on GCF levels of ICTP and IL-1
longitudinally and to examine the relationships between
ICTP, IL-1, and traditional clinical parameters.
MATERIALS AND METHODS
Study Population
Twenty-five subjects exhibiting moderate to severe
chronic periodontitis were recruited for this investiga-
tion. Eligible participants had not received any peri-
odontal therapy for a minimum of 6 months and no
antibiotic treatment for at least 6 months prior to study
inclusion, and were not chronically treated (i.e., 2
weeks or more) with any medication known to affect
periodontal status (e.g., phenytoin, calcium antago-
nists, cyclosporin, coumadin, and non-steroidal anti-
inflammatory drugs). Each subject was monitored at
8 sites at baseline (prior to SRP), and 1, 3, and
6 months after treatment. Four shallow (PD <4 mm)
and 4 deep (PD ≥5 mm) sites were monitored in each
subject for both marker levels (i.e., ICTP, IL-1) and
clinical parameters. ICTP and IL-1 levels were deter-
mined at different sites within each subject (i.e., 2 shal-
low/2 deep sites per mediator for a total of 8 sites).
Sites sampled for ICTP and IL-1 levels were designated
as ICTP sites and IL-1 sites, respectively. After the
baseline procedures (i.e., GCF sampling and clinical
measurements) were completed, SRP was performed
using hand and ultrasonic instrumentation. A maxi-
mum of 2 sessions within 14 days with no time limi-
tation was allowed to complete each subject. Local
anesthetic was used at the discretion of the clinician.
Gingival crevicular fluid sampling (i.e., ICTP, IL-1) and
clinical measurements were repeated at 1, 3, and 6
months. No additional therapy was administered over
the following 6 months. This study was approved by
the Institutional Review Boards at both the University
of Michigan and University at Stony Brook, and
informed consent was obtained in writing from each
subject prior to study commencement.
Clinical Measurements
Clinical measurements were completed at a total of
200 sites (i.e., 25 subjects × 8 sites/subject) at base-
line, 1, 3, and 6 months. The parameters recorded
included: 1) probing depth (PD) measured from the
gingival margin to the base of the pocket in millime-
ters; 2) clinical attachment level (CAL) measured from
either the cemento-enamel junction (CEJ) or restora-
tion margin to the base of the pocket in millimeters; and
3) bleeding on probing (BOP) recorded dichotomously
as 0 or 1. All clinical measurements were performed
after GCF sampling using a manual probe.§ Five exam-
iners (from 2 test centers) performed all clinical mea-
surements and were calibrated prior to the study to
ensure adequate intra- and interexaminer reliability.
Interexaminer reliability was determined using the
intraclass correlation coefficient22 to compare an expe-
rienced examiner designated as the gold standard to
the 5 examiners participating in this study. The intra-
class correlation coefficients for PD and CAL mea-
surements ranged from 0.90 to 0.97 and 0.85 to 0.94,
respectively. Intra-examiner reliability was determined
utilizing the percent agreement within 1 mm between
2 passes and a weighted kappa statistic. The percent
agreement within 1 mm ranged from 95.5% to 97.3%
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and 90.0% to 95.1% for PD and CAL measurements,
respectively. The weighted kappa statistic ranged from
0.92 to 0.97 and 0.88 to 0.92 for PD and CAL mea-
surements, respectively.
Gingival Crevicular Fluid Sampling and Analysis
The area around each site sampled was dried and
supragingival plaque removed. Gingival crevicular fluid
was collected for 30 seconds using methylcellulose
strips. Each strip was placed gently into the gingival
crevice until slight resistance was felt and volume
determined.¶ Following collection and volume deter-
mination, the sample was kept on ice for transport to
the laboratory and stored at −20°C. For ICTP, the des-
ignated frozen samples were thawed at room temper-
ature and proteins eluted by centrifugation with 20 ml
phosphate buffered saline (PBS) 5× at 1,500 × g for 5
minutes. The PBS solution contained 15 nM aprotenin,#
1 mM phenylmethylsulfonylfluoride (PMSF#), and 0.1%
human serum albumin (HSA). Levels of ICTP were
determined using a radioimmunoassay technique**
as previously described.23 The described technique
has been shown to produce >90% efficiency of ICTP
recovery.8
The IL-1β content was determined by using a com-
mercially available enzyme-linked immunosorbent
(ELISA) assay†† that is based on a double antibody
sandwich technique, as described by Payne et al.24
After the designated IL-1 samples were thawed at
room temperature and proteins eluted, plates pre-
coated with a monoclonal antibody specific for human
interleukin-1β were incubated with 100 µl of standard
or sample and an acetylcholinesterase: anti-IL-1β Fab’
conjugate, followed by development with Ellman’s
reagent. Plates then were read at 405 nm. The assay
has a sensitivity of detection of 1.5 pg/ml IL-1β.24 Both
ICTP and IL-1 were reported as total amounts per time
of collection (pg/30-second sample).
Statistical Analysis
Clinical parameters and marker levels at various time
intervals (i.e., baseline, 1-, 3-, and 6-month visits)
were compacted and analyzed using repeated mea-
sures analysis of variance. Given significance at the
0.05 level, pairwise comparisons were performed
using Fisher’s protected t tests. Traditional clinical
parameters (i.e., PD, CAL, BOP) were compared to
ICTP and IL-1 levels utilizing correlation coefficients




Characteristics of the study group at baseline are pre-
sented in Table 1. The cohort comprised 64% females
and 48% smokers. The majority of the sites exhibited
BOP at initial presentation (71.5%). The baseline PD
and CAL measurements ± standard error were 4.27 ±
0.12 mm and 4.30 ± 0.13 mm, respectively. No sig-
nificant differences (P <0.05) were identified at base-
line in regards to PD, CAL, and BOP between sites
sampled for ICTP and IL-1. One patient relocated to
another area and was not available for the 6-month
examination. A total of 792 sites were therefore avail-
able for analysis after excluding the 6-month data (8
sites) of one subject.
Clinical Measurements, ICTP Levels, and IL-1
Levels at Deep and Shallow Sites
Scaling and root planing effects on clinical parameters
at all sites are presented in Table 2. Significant
improvements in PD, CAL, and BOP were observed at
1, 3, and 6 months in all sites (P <0.01). The mea-
surements recorded for PD, CAL, and BOP stratified for
deep/shallow status are presented in Table 3.
Probing depth measurements were significantly
reduced at all time intervals following SRP at deep
(P <0.0001) and shallow (P <0.04) sites (Table 3). Deep








PD (mean ± SE) 4.27 ± 0.12 mm
CAL (mean ± SE) 4.30 ± 0.13 mm
Table 2.
Clinical Response to Scaling and Root
Planing at All Sites
Time PD ± SE CAL ± SE BOP ± SE
(mm) (mm) (%)
Baseline 4.27 ± 0.12 4.30 ± 0.13 71.5 ± 3.2
1 month 3.70 ± 0.10* 3.91 ± 0.12* 59.0 ± 3.5†
3 months 3.54 ± 0.09* 3.76 ± 0.11* 53.0 ± 3.5*
6 months 3.66 ± 0.10* 3.94 ± 0.12* 50.0 ± 3.6*
* P <0.0001.
† P <0.01.
 Pro Flow, Inc., Amityville, NY.
¶   Periotron 6000, Harco Electronics, Tustin, CA.
#   Sigma Chemical Company, St. Louis, MO.
** DiaSorin Inc., Stillwater, MN.
†† Cayman Chemical Company, Ann Arbor, MI.
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CAL after mechanical therapy at all time intervals
(Table 3). Deep sites exhibited significant (P <0.01)
reductions in the percentage of BOP following mechan-
ical therapy. The percentage of BOP at shallow sites
was significantly (P <0.01) reduced at 3 and 6 months.
The absolute amounts of ICTP (pg/site) and IL-1
(pg/site) collected over 30 seconds at deep and shal-
low sites are presented in Figures 1 and 2, respec-
tively. Both ICTP and IL-1 levels were significantly
greater (P <0.001) at sites exhibiting moderate to
severe pocket depths. Non-surgical mechanical ther-
apy did not significantly reduce ICTP and IL-1 levels
over the 6-month period.
Association of ICTP and IL-1 With Clinical
Parameters
The correlations of ICTP and IL-1 with traditional clin-
ical parameters are presented in Table 4. Overall, ICTP
exhibited a stronger association than IL-1 to the clini-
cal parameters studied. A modest correlation (r = 0.40;
P <0.001) existed between ICTP levels and clinical
attachment loss. Other associations were weak, but
significant (P <0.001).
Effect of Smoking Status on ICTP and IL-1 Levels
Figures 3 and 4 illustrate ICTP and IL-1 levels, respec-
tively, exhibited in smokers and non-smokers. In non-
smoking patients, a significant reduction in ICTP lev-
els was observed at the 3- and 6-month time point (P
<0.02). A significant reduction in IL-1 levels was
observed at the 3-month time point (P <0.005). Base-
line ICTP levels in non-smokers were significantly
higher compared to smokers (P <0.05).
DISCUSSION
Accurate identification of periodontal sites exhibiting
disease progression or at risk of future deterioration
has proven elusive. Current methods to identify disease
progression include 2 probing or radiographic exami-
nations performed over a specific time interval (e.g.,
6 months) to detect destructive changes. Therefore,
diagnosis of progression occurs only after significant
periodontal destruction has transpired. Limitations in
measurement reliability also prevent accurate assess-
ment of a patient’s response to therapy. Host factors
in the GCF associated with the anatomic events of
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Table 3.
Clinical Response to Scaling and Root
Planing at Deep and Shallow Sites
Time PD ± SE CAL ± SE BOP ± SE
(mm) (mm) (%)
Baseline
Deep 5.66 ± 0.13 5.64 ± 0.15 87.0 ± 3.4
Shallow 2.89 ± 0.09 2.97 ± 0.10 56.0 ± 5.0
1 month
Deep 4.68 ± 0.14* 4.90 ± 0.18* 71.0 ± 4.6‡
Shallow 2.73 ± 0.07† 2.92 ± 0.08 47.0 ± 5.0
3 months
Deep 4.41 ± 0.13* 4.65 ± 0.16* 70.0 ± 4.6‡
Shallow 2.68 ± 0.08† 2.87 ± 0.09 36.0 ± 4.8‡
6 months
Deep 4.60 ± 0.14* 4.96 ± 0.16* 60.4 ± 5.0‡





Mean ICTP levels ± SE (pg/site) at deep and shallow sites. *Significant
differences (P <0.001) observed between deep and shallow sites at
all time points.
Figure 2.
Mean IL-1 levels ± SE (pg/site) at deep and shallow sites. *Significant
differences (P <0.001) observed between deep and shallow sites at
all time points.
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periodontitis may be useful as markers for identifying
the current status of a patient and predicting future
disease progression.25 A biochemical marker specific
for bone degradation would assist in the differentia-
tion of gingival inflammation from active periodontal
destruction.26 The results of this longitudinal study
demonstrate that higher levels of both a bone-specific
marker (ICTP) and a cytokine associated with bone
resorption (IL-1) are present at sites exhibiting mod-
erate to severe periodontitis. In addition, utilization of
non-surgical mechanical therapy did not significantly
reduce these biochemical markers associated with
bone resorption over a 6-month period.
Previous reports analyzing ICTP levels in GCF have
consistently compared total amounts of GCF versus
concentration, and the most predictive results were
found when total amounts were normalized by the time
of collection.8-11 The mean total amount of ICTP pre-
sent at baseline in this cohort of periodontitis subjects
was similar to previous investigations that measured
ICTP levels in untreated periodontitis subjects.8,11,27
In contrast, Palys et al.9 reported lower ICTP levels
among a group of previously treated periodontitis sub-
jects participating in a periodontal maintenance pro-
gram. In addition, these investigators measured ICTP
at multiple sites within a subject, providing substantially
more healthy than diseased sites for analysis. In the
present study, significantly higher ICTP levels were
identified at sites exhibiting deep probing depth mea-
surements. Talonpoika and Hämäläinen27 utilized a
similar stratification scheme based upon probing depth
and also reported significantly higher ICTP levels
among untreated periodontitis subjects at sites with
deep PD (i.e., 4 to 10 mm). However, Palys et al.9
reported no significant differences in ICTP levels at
sites exhibiting different PD among a cohort of treated
periodontitis patients. These investigators did detect
higher levels of ICTP at shallow sites in both a gin-
givitis and periodontitis cohort compared to peri-
odontally healthy subjects. Overall, ICTP levels were
weakly associated to clinical parameters, with peri-
odontal attachment loss demonstrating a modest rela-
tionship. The presence of previous attachment loss
has been identified as a primary risk factor for peri-
odontal disease progression.28
IL-1 levels expressed as absolute amounts were also
greater at sites exhibiting significant PD measurements.
The positive relationship between absolute amounts
of IL-1 and greater PD has been previously
reported.21,29 However, consistent with previous inves-
tigations,21,30 no significant differences were detected
between deep and shallow sites in IL-1 levels expressed
as a concentration (data not shown). Local concen-
1049
Table 4.






* Correlation coefficient significant (P <0.001).
Figure 3.
Mean ICTP levels ± SE in smokers versus non-smokers. *Significant
reduction (P <0.02) in ICTP levels observed at 3 and 6 months in
non-smokers only. †Baseline ICTP levels in non-smokers were
significantly higher (P <0.05) compared to smokers.
Figure 4.
Mean IL-1 levels ± SE in smokers versus non-smokers. *Significant
reduction (P <0.005) in IL-1 levels observed at 3 months in non-
smokers only.
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trations of IL-1 and ICTP in GCF varied considerably
among subjects and sites, and thus all GCF data were
preferably presented on a pg/site basis.
A single episode of non-surgical mechanical ther-
apy did not significantly reduce ICTP or IL-1 levels at
any of the monitored time periods. Previous studies
utilizing either mechanical8,27 or chemotherapeutic
agents11 have demonstrated reductions in ICTP levels
following periodontal therapy. In the present study,
numerically lower ICTP levels were observed at 1 and
3 months following treatment. The lack of significance
may be due to the presence of inflammation as evi-
denced by the high percentage of bleeding on prob-
ing sites throughout the 6-month period (Table 3). IL-1
levels also did not diminish significantly following
mechanical treatment. Conflicting results have been
reported regarding the effect of periodontal treatment
on IL-1 levels.19,21,29 Reinhardt et al.19 reported no
significant differences in IL-1 levels 6 months after
scaling and root planing. However, sites in the same
cohort treated with periodontal surgery exhibited sig-
nificant increases in IL-1 levels over the same time
period. More recently, Engebretson et al.30 reported
that changes in IL-1 levels following treatment were
dependent upon the subjects’ composite genotype for
the polymorphic IL-1β gene cluster. Significant reduc-
tions in IL-1 concentrations after SRP were detected
only in subjects who did not possess the periodonti-
tis-associated genotype. Stratification of subjects based
upon IL-1 genotype status may be indicated in future
clinical trials evaluating novel diagnostic or treatment
procedures.
Stratification of subjects by smoking status revealed
a different response to scaling and root planing in
relation to biochemical mediator levels. No signifi-
cant differences in ICTP levels were present in smok-
ers post-treatment. However, non-smokers exhibited a
significant decrease in ICTP levels at the 3- and 6-
month time points (P <0.02) and in IL-1 levels at the
3-month time point (P <0.005). It is well documented
that both non-surgical and surgical periodontal thera-
pies are less effective in smokers and recurrence of dis-
ease is more likely in smokers after periodontal treat-
ment.31-34 Interestingly, in the present study, both
smokers and non-smokers exhibited similar improve-
ments in clinical parameters following treatment (data
not shown). However, it is plausible that the improve-
ments observed in the periodontium at an anatomical
level may not represent the metabolic state of the tis-
sues and subsequent risk for disease progression asso-
ciated with smoking.
The incidence of disease progression among all ICTP
sites utilizing a 1 mm and 2 mm threshold were 12%
(12/100) and 3% (3/100), respectively. The reduced
incidence of disease progression was due to the admin-
istration of treatment at the baseline visit. A prelimi-
nary analysis was performed to evaluate the associa-
tion between elevated ICTP levels at baseline and sub-
sequent disease progression (data not shown). Utiliz-
ing a site-based analysis and a threshold value of ≥240
pg/site ICTP at baseline, the odds ratio of a site exhibit-
ing ≥1 mm attachment loss at 1 month was 3.7 (C.I.
= 1.1 to 12.7; P = 0.036). This result suggests that sites
with elevated ICTP at baseline were at greater risk of
demonstrating attachment loss during the follow-up
period. However, the calculation of a subject-based
odds ratio to adjust for patient effects was not feasi-
ble due to the limited number of sites sampled in each
individual. Limitations associated with not controlling
for patient effects include the calculation of unreliable
Type I and Type II error rates, and failure to obtain a
correct assessment of causal relationships between
site-specific variables.35 In a previous study, ICTP was
found to be highly sensitive and predictive for future
radiographic bone loss as measured by digital radio-
graphy.8 Future longitudinal studies on untreated or
maintenance populations are warranted to specifically
evaluate the relationship between C-telopeptide pyridi-
noline cross-links and periodontal disease progression.
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